News
After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit ...
Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...
Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $481.56, ...
Vertex Pharmaceuticals (VRTX) posts strong Q2 earnings and revenue growth but faces a 17% stock drop after mid-stage pain drug failure. Read more here.
Investor's Business Daily on MSN6h
Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat
Vertex stock nose-dived Tuesday after the biotech company said it wouldn't advance its next-generation pain drug into ...
StockStory.org on MSN7h
Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today
What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the ...
Since becoming Vertex's top scientist in 2015, Altshuler has helped the company become an industry powerhouse. He’ll depart ...
Vertex Pharmaceuticals stock fell after quarterly earnings and revenue beat analysts’ expectations, overshadowed by bad news ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback